BioLineRx Acquires CrystaVix JAK1/2 Inhibitor Program
Ticker: BLRX · Form: 6-K · Filed: May 30, 2024 · CIK: 1498403
Sentiment: neutral
Topics: acquisition, drug-development, pipeline-expansion
Related Tickers: BCRX
TL;DR
BioLineRx buys CrystaVix from BioCryst for myelofibrosis, closing Q3 2024.
AI Summary
BioLineRx Ltd. announced on May 30, 2024, that it has entered into a definitive agreement to acquire BioCryst Pharmaceuticals' CrystaVix program, a novel oral JAK1/2 inhibitor for myelofibrosis. The acquisition is expected to close in the third quarter of 2024 and will be funded through a combination of cash on hand and a new credit facility.
Why It Matters
This acquisition could expand BioLineRx's pipeline with a promising drug candidate for myelofibrosis, potentially leading to new treatment options for patients.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions and regulatory approvals, and the success of the CrystaVix program is not guaranteed.
Key Numbers
- Q3 2024 — Expected Closing (Anticipated timeframe for the acquisition to be finalized.)
Key Players & Entities
- BioLineRx Ltd. (company) — Acquiring company
- BioCryst Pharmaceuticals (company) — Seller of CrystaVix program
- CrystaVix (drug_program) — Acquired asset
- JAK1/2 inhibitor (drug_class) — Mechanism of action for CrystaVix
- myelofibrosis (disease) — Target indication for CrystaVix
- May 30, 2024 (date) — Announcement date
- third quarter of 2024 (date) — Expected closing date of acquisition
FAQ
What is the primary purpose of this Form 6-K filing?
This Form 6-K filing is to report a press release issued by BioLineRx Ltd. on May 30, 2024, concerning the acquisition of BioCryst Pharmaceuticals' CrystaVix program.
What is the CrystaVix program?
CrystaVix is a novel oral JAK1/2 inhibitor program being acquired by BioLineRx from BioCryst Pharmaceuticals, intended for the treatment of myelofibrosis.
When is the acquisition of CrystaVix expected to be completed?
The acquisition of the CrystaVix program is expected to close in the third quarter of 2024.
How will the acquisition of CrystaVix be funded?
The acquisition will be funded through a combination of BioLineRx's cash on hand and a new credit facility.
What is the principal executive office address of BioLineRx Ltd.?
The principal executive offices of BioLineRx Ltd. are located at 2 HaMa’ayan Street, Modi’in 7177871, Israel.
Filing Stats: 191 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2024-05-30 07:16:29
Filing Documents
- zk2431529.htm (6-K) — 9KB
- exhibit_1.htm (EX-99) — 17KB
- image0.jpg (GRAPHIC) — 403KB
- 0001178913-24-001889.txt ( ) — 582KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On May 30, 2024, the Registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K. This Form 6-K, and the first and fourth paragraphs of the press release attached to this Form 6-K as Exhibit 1 are hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: May 30, 2024